- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -

- The Company also has allowed and issued patents in the US, Australia, and Japan covering their BDS with botulinum toxin for the treatment of hyperhidrosis -

SAN DIEGO, CA / ACCESS Newswire / April 2, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has accepted its patent application for its topical dermal filler program utilizing its BDS. The patent, entitled "Compositions for the treatment of conditions by dermal fillers," (Australian Patent Application No. 2020315876) continues to strengthen Dermata's global intellectual property portfolio for its BDS programs. The patent will be automatically issued three months after acceptance unless a third party files an opposition.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.